20.500.12556/DiRROS-27873 Advancing allogeneic hematopoietic stem cell transplantation outcomes through immunotherapy a comprehensive review of optimizing non-CAR donor T-lymphocyte infusion strategies Optimized use of prophylactic or therapeutic donor lymphocyte infusions (DLI) is aimed at improving clinical outcomes in patients with malignant and non-malignant hematological diseases who have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT). Memory Tlymphocytes (CD45RA−/CD45RO+) play a crucial role in immune reconstitution post-HSCT. The infusion of memory T cells is proven to be safe and effective in improving outcomes due to the enhanced reconstitution of immunity and increased protection against viremia, without exacerbating graft-versus-host disease (GVHD) risks. Studies indicate their persistence and efficacy in combating viral pathogens, suggesting a viable therapeutic avenue for patients. Conversely, using virus-specific T cells for viremia control presents challenges, such as regulatory hurdles, cost, and production time compared to CD45RA-memory T lymphocytes. Additionally, the modulation of regulatory T cells (Tregs) for therapeutic use has become an important area of investigation in GVHD, playing a pivotal role in immune tolerance modulation, potentially mitigating GVHD and reducing pharmacological immunosuppression requirements. Finally, donor T cell-mediated graft-versus-leukemia immune responses hold promise in curbing relapse rates post-HSCT, providing a multifaceted approach to therapeutic intervention in high-risk disease scenarios. This comprehensive review underscores the multifaceted roles of T lymphocytes in HSCT outcomes and identifies avenues for further research and clinical application hematopoietic stem cell transplantation T lymphocyte memory T cells virus-specific T cells graft-versus-host disease graft-versus-leukemia true false true Angleški jezik Ni določen Neznano 2026-02-26 13:31:59 2026-02-26 13:31:59 2026-02-27 03:58:41 0000-00-00 00:00:00 2024 0 0 Nasl. z nasl. zaslona; Opis vira z dne 23. 3. 2025; str. 1-19 iss. 8, [article no.] 1853 Vol. 12 2024 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 61 2227-9059 10.3390/biomedicines12081853 229915139 RAZ_Braidotti_Stefania_2024.pdf RAZ_Braidotti_Stefania_2024.pdf 1 C731806337BA5C30562FA4349AB37788 2adcefd36a7dc9e8f9ff22885c9be360160b8a53a75c0c7a8613a5aa14bd38aa 3f0cb7ed-130f-11f1-9cb0-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=41017 https://www.mdpi.com/2227-9059/12/8/1853 1 25cf837c-130f-11f1-9cb0-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=41016 Univerzitetni klinični center Ljubljana 0 0 0